Jpmorgan Chase & CO Repare Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Repare Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4 shares of RPTX stock, worth $6. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 85,802 100.0%

Holding current value

Previous $112,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$0.99 - $1.39 $84,940 - $119,259	-85,798 Reduced 100.0%	4 $0
Q4 2024 Feb 12, 2025	BUY	$1.25 - $3.97 $107,247 - $340,618	85,798 Added 2144950.0%	85,802 $112,000
Q4 2023 Feb 12, 2024	SELL	$3.22 - $11.79 $26,233 - $96,053	-8,147 Reduced 99.95%	4 $0
Q3 2023 Nov 14, 2023	BUY	$8.16 - $13.01 $54,125 - $86,295	6,633 Added 436.96%	8,151 $98,000
Q2 2023 Aug 11, 2023	BUY	$8.63 - $12.53 $336 - $488	39 Added 2.64%	1,518 $16,000
Q1 2023 May 11, 2023	BUY	$9.32 - $15.06 $270 - $436	29 Added 2.0%	1,479 $14,000
Q4 2022 Feb 13, 2023	SELL	$12.5 - $18.13 $272,137 - $394,708	-21,771 Reduced 93.76%	1,450 $21,000
Q3 2022 Nov 14, 2022	BUY	$11.57 - $15.59 $12,102 - $16,307	1,046 Added 4.72%	23,221 $282,000
Q2 2022 Aug 11, 2022	SELL	$8.45 - $14.84 $24,200 - $42,501	-2,864 Reduced 11.44%	22,175 $311,000
Q1 2022 May 11, 2022	BUY	$11.38 - $21.88 $14,259 - $27,415	1,253 Added 5.27%	25,039 $356,000
Q4 2021 Feb 10, 2022	SELL	$19.66 - $28.11 $93,738 - $134,028	-4,768 Reduced 16.7%	23,786 $502,000
Q3 2021 Nov 12, 2021	BUY	$25.71 - $35.24 $734,123 - $1.01 Million	28,554 New	28,554 $750,000

Others Institutions Holding RPTX

# of Institutions

Shares Held

30.8M

Call Options Held

163K

Put Options Held

View Full List

About Repare Therapeutics Inc.

Ticker RPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,937,800
Market Cap $65.4M
Description
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...

More about RPTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Repare Therapeutics Inc. Transaction History